Many unresolved questions surrounding the mechanisms of KDM3B and KDM3C in tumorigenesis remain to be disclosed, leaving hope for further pharmacological opportunities to fight cancer using epigenetic therapy. This evidence concerns the gene JMJD1C and cancer.